On Tuesday, Ascendis Pharma ADR got a positive adjustment to its Relative Strength (RS) Rating, from 89 to 92.
This proprietary rating tracks technical performance by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
Decades of market research shows that the stocks that go on to make the biggest gains typically have an 80 or better RS Rating as they begin their biggest climbs.
Here Are 3 Keys For Successful Stock Investing
Ascendis Pharma ADR is still within a buying range after breaking past a 161.00 buy point in a consolidation. Once a stock moves 5% or higher beyond the initial entry, it's considered out of buy range.
The company showed 0% earnings growth in its most recent report. Sales gains came in at 18%.
The company holds the No. 24 rank among its peers in the Medical-Biomed/Biotech industry group. Krystal Biotech, ADMA Biologics and Catalyst Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
